AQUESTIVE THERAPEUTICS INC
NASDAQ: AQST (Aquestive Therapeutics, Inc.)
Last update: yesterday, 1:15AM3.46
-0.25 (-6.61%)
| Previous Close | 3.71 |
| Volume | 3,360,585 |
| Avg. Volume (3M) | 2,388,779 |
| Market Cap | 434,879,456 |
| Price / Sales | 9.58 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2026 |
| Profit Margin | -162.33% |
| Operating Margin (TTM) | -114.13% |
| Diluted EPS (TTM) | -0.650 |
| Quarterly Revenue Growth (YOY) | -41.00% |
| Current Ratio (MRQ) | 6.12 |
| Operating Cash Flow (TTM) | -39.76 M |
| Levered Free Cash Flow (TTM) | -22.57 M |
| Return on Assets (TTM) | -24.63% |
News Mood
-
Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...
06 Nov, 1:05PM
-
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
03 Nov, 3:01PM
AIStockmoo Score
| Value 30% | -1.7 |
| Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | -4.1 |
| Downtrend over the past year. Far below its 52-week high. info | |
| In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on down days. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.1 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mixed or neutral. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 1.2 |
| Insiders net buying recently. Price is below what insiders paid. info | |
| Institutions net +3.33% of shares in their latest 13F filings: 95 holders increased, 78 decreased (quarter to 30 Sep 2026). info | |
| Short interest +15.1% from 31 Aug to 30 Oct 2026, 13.2 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Earnings per share have gone up and down. Made a loss in recent years. info | |
| Below its medium-term trend line. info | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Price is near support. Levels trending down. info | |
| Final Score | -1.70 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Aquestive Therapeutics, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| AQST | 435 M | - | - | - | -1.7 |
| SUPN | 6 B | 27.84% | - | 1.59 | -1.0 |
| ANIP | 2 B | - | 13.74 | 2.57 | -0.1 |
| COLL | 783 M | - | 23.13 | 2.72 | 0.1 |
| TKNO | 480 M | - | - | - | 0.8 |
| TLRY | 279 M | - | - | 0.200 | -2.2 |
Select this tab to load the latest available analysis.
|
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 10.78% |
| % Held by Institutions | 61.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bratton Capital Management, L.P. | 30 Sep 2026 | 9,810,958 |
| Rosalind Advisors, Inc. | 30 Sep 2026 | 2,000,000 |
| Blue Owl Capital Holdings Lp | 30 Sep 2026 | 1,390,632 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DALY RICHARD J | 3.52 | - | 28,025 | 98,648 |
| DAVIS MATTHEW W. | - | 3.55 | -12,500 | -44,360 |
| Aggregate Net Quantity | 15,525 | |||
| Aggregate Net Value ($) | 54,288 | |||
| Aggregate Avg. Buy ($) | 3.52 | |||
| Aggregate Avg. Sell ($) | 3.55 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DAVIS MATTHEW W. | Officer | 12 Nov 2026 | Sell (-) | 7,197 | 3.57 | 25,693 |
| DAVIS MATTHEW W. | Officer | 10 Nov 2026 | Disposed (-) | 5,303 | 3.52 | 18,667 |
| DALY RICHARD J | Director | 10 Nov 2026 | Buy (+) | 28,025 | 3.52 | 98,648 |
Institutions
Institutional ownership: 65.06%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 95 | 11,250,763 |
| Decreased | 78 | 7,172,973 |
| New | 26 | 2,010,558 |
| Sold out | 20 | 1,892,405 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 29,318,686 | 13.2 |
| 15 Oct 2026 | 27,597,742 | 13.9 |
| 30 Sep 2026 | 28,748,212 | 13.1 |
| 15 Sep 2026 | 27,161,738 | 11.8 |
| 31 Aug 2026 | 25,478,782 | 7.2 |
| 14 Aug 2026 | 20,951,747 | 5.2 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 18 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference
WARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will… |
| 16 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision
Aquestive Therapeutics (NASDAQ:AQST) is preparing for a potential U.S. launch of its needle-free treatment for severe allergic reactions, with an FDA decision expected on March 16, 2027, CEO Dan Barber said at the 2026 Jefferies Global Healthcare Conference. The company’s lead product candidate, An… |
| 09 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will… |
| 06 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...
Aquestive Therapeutics Inc (AQST) navigates quarterly revenue fluctuations while advancing Anifilm toward a March 2027 FDA decision and securing a $10 million upfront licensing deal for Libervant. |
| 05 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, today announced that multiple oral and poster… |
| 04 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Aquestive Therapeutics, Inc.'s Q3 2026 earnings call… |
| 04 Nov 2026 | Yahoo Finance |
Aquestive (AQST) Q3 2026 Earnings Call Transcript
Anaphylm's March 2027 FDA date anchors a launch push backed by new funding. |
| 04 Nov 2026 | Yahoo Finance |
What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call
Aquestive Therapeutics (NASDAQ:AQST) said it resubmitted its application for Anaphylm, an epinephrine sublingual film intended for severe allergic reactions, before the end of the third quarter and is preparing for a potential U.S. launch next year if the product receives Food and Drug Administratio… |
| 03 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -30.00% and -31.51%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 03 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics: Q3 Earnings Snapshot
(AP) — Aquestive Therapeutics Inc. (AQST) on Tuesday reported a loss of $16… |
| 03 Nov 2026 | Yahoo Finance |
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approvedCommercial preparations remain on track to support a potential U.S. launch of Anaphylm… |
| 27 Oct 2026 | Yahoo Finance |
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that… |
| 15 Oct 2026 | Yahoo Finance |
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026 WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive… |
| 14 Oct 2026 | Yahoo Finance |
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.Patient market research demonstrated strong preference for buccal film, with 71% of… |
| 29 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc.… |
| 17 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026… |
| 07 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
On August 11, Aquestive Therapeutics (NASDAQ:AQST) reported second-quarter 2026 results and said it remains on track to resubmit its Anaphylm epinephrine film to the FDA in the third quarter of 2026. That single sentence carries the whole story here. A company living and dying by one product… |
| 01 Sep 2026 | Yahoo Finance |
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the… |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |